Qvest Group Acquires OnPrem Solution Partners LLC
8.12.2020 22:50:00 EET | Business Wire | Press release
The Qvest Group, a world-leading systems architect and ICT integrator, today announced the acquisition of the majority of OnPrem Solution Partners LLC, a highly reputed consultancy across the media and entertainment supply chain in the USA. OnPrem’s expertise in business and technology consulting, especially its focus on the digital media supply chain, will complement and extend the Qvest Group’s portfolio and lay the foundation to gain a foothold on the US-American market.
Headquartered in Los Angeles, with additional offices in New York and Austin, OnPrem is an end-to-end solution provider that strategizes, advises, designs and develops technology solutions, leveraging their expertise in content, customers and data for media and entertainment and consumer products industries. The acquisition brings a highly experienced team of more than 250 consultants to deliver solutions in areas such as Digital Media Supply Chain, IP and Rights Management, Data and Analytics, Customer Experience Design, Salesforce and Program Management/PMO to the Qvest Group. OnPrem has built dynamic partnerships with leading technology providers and platforms such as AWS, Salesforce and Microsoft.
“OnPrem strengthens the position of the Qvest Group as a leading partner in digital media, data and cloud management and considerably enhances our capacity to provide clients with added value, scale, and world-class expertise,” said Peter Nöthen, CEO of the Qvest Group. “For Qvest, this is also the steppingstone to the largest market for broadcast & media in the world which significantly raises our international business in technology consultancy and systems integration. Moreover, joining forces with OnPrem enables us to better and directly support worldwide operating clients and it also generates the ground for the growth of our cloud management platform qibb in the US-American market.”
Frank Leal, Partner at OnPrem, agrees: “The leadership at OnPrem is excited and inspired by our new Qvest partnership. With Qvest’s focus on the media industry and quality and their international presence, there was no better fit for us. This transaction creates a worldwide entity that is a partner to CTOs, CIOs and Broadcast Engineers everywhere. Most importantly, we were able to join a leadership team with a similar philosophy on culture and talent, providing additional opportunities for our team members and creating an organization that is a home to the best consultants and engineers in the world.”
The Qvest Group, headquartered in Germany, has offices across Europe, the Middle East, APAC, and Australia. The company has been accelerating the digital transformation of its clients, offering capabilities in technology design consultancy and systems integration, software development, cloud engineering, and technical infrastructure operations.
For OnPrem, Qvest’s service offerings and global scale will help to meet its clients’ growing needs for architecture design, seamless technology integration and realizing large-scaled media infrastructure projects along the entire digital media value chain.
As part of the acquisition, the Qvest Group acquired 55 % of the shares in OnPrem. The contract was signed on December 2, 2020. The partners at OnPrem, Frank Leal, Candice Lu, Christophe Ponsart, Jon Christian, and Vanessa Fiola, along with leadership will continue to build on its long-standing, valued relationships with employees and clients.
About Qvest Group
Qvest is a world-leading systems architect, consultant and ICT integrator in the innovation-driven media industry. The company’s range of services is aligned to the opportunities emerging from an increasingly digital media value chain such as multi-platform content delivery, AI, big data analysis, multi-cloud management and IP infrastructures. Qvest Media’s clients include renowned media networks, telecommunication providers, broadcasters, companies and organizations from the industrial and public sector. Next to the headquarters in Cologne, Qvest Media operates further locations in Europe, the USA, MENA & APAC.
About OnPrem
OnPrem Solution Partners is an end-to-end solution provider that strategizes, advises, designs, develops and integrates world-class technology. Experts in Digital Media Supply Chain, IP and Rights Management, CRM, AI, Data & Analytics, PMO/Project management and custom development, OnPrem connects disparate parts of an organization to enable operational excellence. Based in Los Angeles with offices in New York and Austin Texas, OnPrem offers its expertise within the Media & Entertainment, Consumer Packaged Goods industries and more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208006050/en/
Contact information
Björn Korb
+49 22197776710
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom